- Home
- XBIO vs RDHL Comparison
XBIO vs RDHL Comparison
Compare XBIO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- RDHL
- Stock Information
- Founded
- XBIO N/A
- RDHL 2009
- Country
- XBIO United States
- RDHL Israel
- Employees
- XBIO N/A
- RDHL N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- RDHL Health Care
- Exchange
- XBIO Nasdaq
- RDHL Nasdaq
- Market Cap
- XBIO 4.4M
- RDHL 3.9M
- IPO Year
- XBIO N/A
- RDHL N/A
- Fundamental
- Price
- XBIO $9.83
- RDHL $1.83
- Analyst Decision
- XBIO Hold
- RDHL
- Analyst Count
- XBIO 1
- RDHL 0
- Target Price
- XBIO N/A
- RDHL N/A
- AVG Volume (30 Days)
- XBIO 28.4K
- RDHL 2.9M
- Earning Date
- XBIO 11-11-2025
- RDHL 09-05-2025
- Dividend Yield
- XBIO N/A
- RDHL N/A
- EPS Growth
- XBIO N/A
- RDHL N/A
- EPS
- XBIO N/A
- RDHL N/A
- Revenue
- XBIO $2,446,221.00
- RDHL $9,550,000.00
- Revenue This Year
- XBIO $1.99
- RDHL $381.91
- Revenue Next Year
- XBIO $20.00
- RDHL N/A
- P/E Ratio
- XBIO N/A
- RDHL N/A
- Revenue Growth
- XBIO N/A
- RDHL 157.62
- 52 Week Low
- XBIO $2.20
- RDHL $1.06
- 52 Week High
- XBIO $5.27
- RDHL $9.00
- Technical
- Relative Strength Index (RSI)
- XBIO 95.26
- RDHL 52.81
- Support Level
- XBIO $2.81
- RDHL $1.85
- Resistance Level
- XBIO $3.29
- RDHL $2.61
- Average True Range (ATR)
- XBIO 0.40
- RDHL 0.23
- MACD
- XBIO 0.63
- RDHL -0.01
- Stochastic Oscillator
- XBIO 100.00
- RDHL 22.22
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.